RYZB · RayzeBio

Acquired Company

Bristol Myers Squibb completed its acquisition of RayzeBio on February 26, 2024, and RayzeBio became a wholly owned subsidiary of Bristol Myers Squibb.

RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company is headquartered in San Diego, California.

5505 MOREHOUSE DRIVE, SAN DIEGO, CA, UNITED STATES, 92121, USA

rayzebio.com

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

3.718B

52 Wk Range

$0.00 - $0.00

Previous Close

$62.49

Open

$62.49

Volume

N/A

Day Range

$62.49 - $62.49

Enterprise Value

N/A

Cash

252M

Avg Qtr Burn

-17.26M

Insider Ownership

9.69%

Institutional Own.

89.71%

Qtr Updated

Sep 30^th 2023